- Home
- OZ vs NNNN Comparison
OZ vs NNNN Comparison
Compare OZ & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- NNNN
- Stock Information
- Founded
- OZ 2020
- NNNN 2021
- Country
- OZ United States
- NNNN Germany
- Employees
- OZ N/A
- NNNN N/A
- Industry
- OZ
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OZ
- NNNN Health Care
- Exchange
- OZ Nasdaq
- NNNN Nasdaq
- Market Cap
- OZ 236.3M
- NNNN 267.7M
- IPO Year
- OZ N/A
- NNNN 2025
- Fundamental
- Price
- OZ $63.75
- NNNN $6.43
- Analyst Decision
- OZ
- NNNN
- Analyst Count
- OZ 0
- NNNN 0
- Target Price
- OZ N/A
- NNNN N/A
- AVG Volume (30 Days)
- OZ 6.0K
- NNNN 28.8K
- Earning Date
- OZ 01-01-0001
- NNNN 01-01-0001
- Dividend Yield
- OZ N/A
- NNNN N/A
- EPS Growth
- OZ N/A
- NNNN N/A
- EPS
- OZ N/A
- NNNN 0.06
- Revenue
- OZ $2,675,000.00
- NNNN $8,185,146.00
- Revenue This Year
- OZ N/A
- NNNN N/A
- Revenue Next Year
- OZ N/A
- NNNN N/A
- P/E Ratio
- OZ N/A
- NNNN $118.17
- Revenue Growth
- OZ 18.68
- NNNN 21.95
- 52 Week Low
- OZ $56.77
- NNNN $5.18
- 52 Week High
- OZ $82.89
- NNNN $7.82
- Technical
- Relative Strength Index (RSI)
- OZ 53.29
- NNNN N/A
- Support Level
- OZ $62.95
- NNNN N/A
- Resistance Level
- OZ $64.50
- NNNN N/A
- Average True Range (ATR)
- OZ 0.96
- NNNN 0.00
- MACD
- OZ 0.31
- NNNN 0.00
- Stochastic Oscillator
- OZ 78.43
- NNNN 0.00
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.